Gilead Should Bounce From These Oversold Levels


Gilead (NYSE:GILD) really broke down after its 2nd quarter earnings. This stock cant go much lower in my view despite its obvious problems in HCV. Furthermore the biotech sector continues to go from strength to strength. I cannot see Gilead stock continuing to trade down with the biotech sector going the other way. Furthermore I believe the company’s HCV sales will eventually settle down. Despite its problems, it is still the strongest player in the HCV space at present. Risk/reward definitely to the upside here.


About Individual Trader

Helping You Navigate The Markets For Profit
This entry was posted in Stock Picks and tagged . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s